Journal of Crohn's & colitis最新文献

{"title":"Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn's disease: results from the phase 3 VIVID-1 study.","authors":"Miguel Regueiro, Monika Fischer, Peter Bossuyt, Marijana Protic, Kristina Traxler, Guanglei Yu, Huaiyu Zang, Aisha Vadhariya, Tadakazu Hisamatsu, Pascal Juillerat, Alessandro Armuzzi, Javier P Gisbert, Alissa Walsh","doi":"10.1093/ecco-jcc/jjaf100","DOIUrl":"10.1093/ecco-jcc/jjaf100","url":null,"abstract":"<p><strong>Background: </strong>Fatigue is a debilitating multifactorial symptom experienced by patients with Crohn's disease (CD). Mirikizumab, an anti-interleukin-23p19 antibody, demonstrated significant efficacy and safety in the patients with moderately to severely active CD. This analysis investigated the impact of mirikizumab on fatigue and the association between changes in clinical, endoscopic, and patient-reported outcomes with improvement in fatigue from baseline in the Phase 3 VIVID-1 study.</p><p><strong>Methods: </strong>Adult patients with moderately to severely active CD that failed at least 1 biologic agent or conventional therapy were randomized to receive mirikizumab or placebo. Fatigue was assessed via the validated Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire. Fatigue associations with patient-reported outcomes, endoscopic, and clinical measures were assessed via Pearson correlation analysis.</p><p><strong>Results: </strong>At Week 12, 43% and 33%, and at Week 52, 46% and 36% of mirikizumab-treated patients achieved ≥ 6 and ≥ 9 fatigue score improvements vs placebo (Week 12, 31%, 22%; Week 52, 20%, 16%), respectively. Baseline fatigue scores were strongly associated with depressive symptoms and moderately associated with quality of life (QoL) at baseline. Improvements in fatigue at Weeks 12 and 52 were strongly associated with QoL and patient-reported outcomes and weakly with objective markers of inflammation and disease activity.</p><p><strong>Conclusions: </strong>Mirikizumab-treated patients with CD achieved higher rates of clinically meaningful improvement in fatigue vs placebo at Weeks 12 and 52, which correlated with improvement in clinical and patient-reported outcomes. Baseline fatigue severity was strongly associated with depressive symptoms in VIVID-1 (NCT03926130).</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Creeping fat in Crohn's disease: an immunometabolic imbalance worth targeting?","authors":"Sare Verstockt","doi":"10.1093/ecco-jcc/jjaf109","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf109","url":null,"abstract":"","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":"19 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lysophosphatidylcholine-induced aberrant adipogenesis in mesenchymal stem cells and impaired antibacterial function in adipocytes of creeping fat.","authors":"Fangting Wu, Wenting Xie, Anqi Yu, Xiaoxia Lin, Ting Ouyang, Jieying Fei, Xi Liu, Hui Yang, Da Zhang, Jintao Shi, Weidong Wang, Miaoxing Huang, Guiquan Chen, Fang Xie, Fengfei Wu, Lan Bai","doi":"10.1093/ecco-jcc/jjaf019","DOIUrl":"10.1093/ecco-jcc/jjaf019","url":null,"abstract":"<p><strong>Background and aim: </strong>Creeping fat (CF) in Crohn's disease (CD) is characterized by hyperplastic mesenteric adipose tissue (MAT) encasing fibrotic intestinal segments. Creeping fat exhibits disruptions in microbiota and lipid metabolism, particularly in lysophosphatidylcholine (LPC). This study aims to elucidate the impact of LPC on adipogenic differentiation of mesenchymal stem cells in CF and its effects on immune defense functions in the differentiated adipocytes.</p><p><strong>Methods: </strong>Isolated adipocytes of MAT from CD and non-CD patients were analyzed for bacterial counts and composition using AQ-PCR and 16S rRNA. RNA sequencing was performed on isolated adipocytes to assess functionality. Lysophosphatidylcholine levels in CD patients and their effects on adipocyte immune defense were measured using lipidomics, ELISA, and bacterial killing assays. A trinitrobenzenesulfonic acid (TNBS)-induced colitis model was used to measure LPC levels in plasma and gene expression in MAT.</p><p><strong>Results: </strong>Significant shifts in microbial diversity and bacterial load were observed in CF-derived adipocytes, characterized by increased colonization by pathogenic bacteria and diminished antibacterial capabilities. Sequencing analysis revealed downregulation of antibacterial genes, including SAA1/2, and upregulation of lipid metabolism-related genes. Lipidomic analysis of CF showed elevated LPC levels, a pro-inflammatory lipid also found in plasma of CD patients. In vitro experiments demonstrated LPC promotes adipogenesis through EGR2 while impairing adipocytes' antibacterial immunity. These findings were consistent in the TNBS-treated mouse model, where increased LPC levels in the blood, and a significant reduction in SAA1/2-positive adipocytes were noted.</p><p><strong>Conclusions: </strong>Lysophosphatidylcholine-induced aberrant adipogenesis in CF is a newly identified pathological feature in CD patients and a potential therapeutic target.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ST6GAL1 promotes IBD B cell recruitment to the inflamed colon in a CD22-dependent mechanism.","authors":"Li-Juan Liu, Tanja M Müller, Mark Dedden, Sebastian Schramm, Moritz Leppkes, Raja Atreya, Imke Atreya, Markus F Neurath, Sebastian Zundler","doi":"10.1093/ecco-jcc/jjaf097","DOIUrl":"10.1093/ecco-jcc/jjaf097","url":null,"abstract":"<p><strong>Background and aims: </strong>Since the discovery that auto-reactive anti-αvβ6 integrin antibodies are associated with ulcerative colitis, cells from the B cell lineage, especially plasmablasts and plasma cells have increasingly come into the focus of research on inflammatory bowel disease. However, the mechanisms regulating their recruitment from the circulation to the gut remain poorly understood. Here, we explored whether the B cell-specific lectin CD22 interacts with endothelial α2,6-linked sialic acid residues attached by ST6GAL1 to mediate such recruitment in IBD.</p><p><strong>Methods: </strong>Flow cytometry, transcriptomics, immunofluorescence, dynamic adhesion assays, and in vivo homing assays were employed to study the role of ST6GAL1 and CD22 in regulating B cell trafficking to the inflamed gut.</p><p><strong>Results: </strong>Plasmablasts were relatively reduced in the circulating B cell compartment of patients with IBD. CD22 was expressed on the majority of B cells and plasmablasts. ST6GAL1 was expressed on vessels in the colon and its expression was nominally increased in IBD. The interaction of CD22 with α2,6-linked sialic acids controlled dynamic B cell adhesion in vitro and, consistently, the in vivo gut homing of IBD B cells to the inflamed colon could be blocked by anti-CD22 antibodies in humanized mice.</p><p><strong>Conclusions: </strong>Our findings suggest that endothelial ST6GAL1 creates a pro-adhesive microenvironment rich in α2,6-sialic acids that engage CD22 on circulating B cells and plasmablasts to promote their recruitment into the inflamed gut mucosa. This pathway might be a novel target to interfere with B lineage cell homing and local auto-antibody production.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144259713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey.","authors":"Gionata Fiorino, Alissa Walsh, Michel Adamina, Manuel Barreiro-de Acosta, Mariam P Ali, Martin Bortlik, Johan Burisch, Axel Dignass, David Drobne, Omar Faiz, Marc Ferrante, Liselotte Fierens, Lihi Godny, Anna Gojdicova, Marietta Iacucci, Susanna Jӓghult, Konstantinos Karmiris, Julien Kirchgesner, Sophie Restellini, Francesca Rosini, Dror Shouval, Welmoed Van Deen, Henit Yanai, Edyta Zagórowicz, Catarina Fidalgo","doi":"10.1093/ecco-jcc/jjaf094","DOIUrl":"10.1093/ecco-jcc/jjaf094","url":null,"abstract":"<p><strong>Background and aims: </strong>Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, require an interdisciplinary approach for diagnosis, monitoring, and management. The European Crohn's and Colitis Organisation (ECCO) has developed evidence-based recommendations and quality care standards for IBD management, but gaps between these standards and real-world practice persist. The E-QUALITY task force aimed to evaluate the structure, processes, and outcomes of IBD units across Europe and identify barriers to achieving ECCO quality standards.</p><p><strong>Methods: </strong>A web-based survey was conducted from September 2022 to October 2024 among 245 institutions in 35 European countries. The survey assessed unit structure, interdisciplinary care, services, facilities, and barriers to achieving quality care standards. Subgroup analyses were performed based on institution type, patient volume, and geographical distribution.</p><p><strong>Results: </strong>Formal IBD units were present in 68% of institutions, with interdisciplinary teams available in 94%. Institutions with >500 active patients were more likely to meet ECCO standards for interdisciplinary care, quality indicators, and patient support but faced challenges such as lack of time and referral pathways. Geographical disparities significantly influenced the availability of resources and services. Key barriers to quality care included lack of time (71%), personnel (69%), and funding (45%).</p><p><strong>Conclusions: </strong>Significant gaps in quality care standards remain across European IBD units. Enhanced support from ECCO, by education and position papers/guidelines may help bridge these gaps.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144287661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.","authors":"Gionata Fiorino, Catarina Fidalgo, Michel Adamina, Manuel Barreiro-de Acosta, Mariam P Ali, Martin Bortlik, Johan Burisch, Axel Dignass, David Drobne, Omar Faiz, Marc Ferrante, Liselotte Fierens, Lihi Godny, Anna Gojdicova, Marietta Iacucci, Susanna Jӓghult, Konstantinos Karmiris, Julien Kirchgesner, Sophie Restellini, Francesca Rosini, Dror Shouval, Henit Yanai, Edyta Zagórowicz, Alissa Walsh","doi":"10.1093/ecco-jcc/jjaf105","DOIUrl":"10.1093/ecco-jcc/jjaf105","url":null,"abstract":"<p><strong>Background and aims: </strong>Quality of care in inflammatory bowel disease (IBD) management is crucial for early detection and prevention of disease progression and complications. The European Crohn's and Colitis Organisation (ECCO) developed evidence-based recommendations and quality of care (QoC) standards for IBD management, but gaps between these standards and real-world practices still exist. The E-QUALITY task force aimed to evaluate processes related to quality standards of IBD diagnosis and management across European institutions and identify barriers to meet ECCO QoC standards.</p><p><strong>Methods: </strong>A web-based survey was conducted from September 2022 to October 2024 among 245 institutions in 35 European countries. The survey assessed processes used to diagnose and monitor disease activity, to prevent infections, and to detect colorectal cancer in IBD. Subgroup analyses were performed based on institution type, patient volume, and geographical distribution.</p><p><strong>Results: </strong>Across participating European centers, most ECCO recommendations were followed in 85% of institutions. Monitoring disease activity and severity within the recommended time occurred in 75% of institutions, although audit mechanisms are lacking in the majority of centers. The main challenges are difficulties in scheduling endoscopy/imaging within the recommended time frame, lack of uniform behavior among physicians in the same unit, and patients' reluctance to undergo regular monitoring.</p><p><strong>Conclusion: </strong>Significant gaps in QoC standards remain across European IBD units. Most units lack specific auditing mechanisms to track true standard compliance. Enhanced support from ECCO, through education on guidelines and implementation strategies, and adaptation of recommendations to accommodate real-world challenges may help to bridge these gaps.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antigen-driven expansion of public clonal T-cell populations in inflammatory bowel diseases.","authors":"Mitchell Pesesky, Ramit Bharanikumar, Lionel Le Bourhis, Hesham ElAbd, Elisa Rosati, Cara L Carty, Namita Singh, Bernd Bokemeyer, Stefan Schreiber, Siegfried Görg, Marco Garcia Noceda, Paidamoyo Chapfuwa, Rachel M Gittelman, Damon May, Jennifer N Dines, Wenyu Zhou, Ian M Kaplan, Thomas M Snyder, Harus Jabran Zahid, Julia Greissl, Haiyin Chen-Harris, Bryan Howie, Andre Franke, Harlan S Robins, Matthieu Allez","doi":"10.1093/ecco-jcc/jjaf048","DOIUrl":"10.1093/ecco-jcc/jjaf048","url":null,"abstract":"<p><strong>Background and aims: </strong>Inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC), are known to involve shifts in the T-cell repertoires of affected individuals, including clonal expansion of abundant T-cell populations in CD mucosal tissue. There are also differential human leukocyte antigen (HLA) risk and protective alleles between CD and UC, implying CD- and UC-specific repertoire changes that have not yet been identified. In this study, we aimed to identify specific, antigen-driven T-cell signatures in CD and UC.</p><p><strong>Methods: </strong>We performed ImmunoSequencing on blood samples from 3853 CD cases, 1803 UC cases, and 5596 healthy controls (HCs). We identified public T cell receptor β (TCRB) sequences significantly enriched in CD or UC cases.</p><p><strong>Results: </strong>We determine that there is more expansion across clonotypes in CD, but not UC, compared with HCs. Strikingly, from blood, we identify public TCRBs specifically expanded in CD or UC. These sequences are more abundant in intestinal mucosal samples, form groups of similar CDR3 sequences, and can be associated with specific HLA alleles. Although the prevalence of these sequences is higher in ileal and ileocolonic CD than colonic CD or UC, the TCRB sequences themselves are shared across CD and not between CD and UC.</p><p><strong>Conclusions: </strong>There are peptide antigens that commonly evoke immune reactions in IBD cases and rarely in non-IBD controls. These antigens differ between CD and UC. CD, particularly ileal CD, also seems to involve more substantial changes in clonal population structure than UC, compared to HCs.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143694906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized controlled trial of antibiotics targeting adherent and invasive Escherichia coli versus placebo in Crohn's disease: the TEOREM trial.","authors":"Franck Carbonnel, Nicolas Barnich, Patricia Lepage, Xavier Hébuterne, Christophe Michiels, Cyrielle Gilletta, Pauline Wils, David Laharie, Romain Altwegg, Mathieu Allez, Yoram Bouhnik, Antoine Meyer, Clémence Breton, Hélène Agostini, Domitille Molinari, Ryan Balfour Sartor, Jean Yves Mary, Jean Frédéric Colombel, Caroline Chevarin, Frédéric Faure, Anouk Walter-Petrich, Sylvie Chevret, Anthony Buisson","doi":"10.1093/ecco-jcc/jjaf093","DOIUrl":"10.1093/ecco-jcc/jjaf093","url":null,"abstract":"<p><strong>Background: </strong>A subset of patients with ileal Crohn's disease (CD) are colonized with adherent-invasive Escherichia coli (AIEC).</p><p><strong>Objective: </strong>This prospective trial tested the efficacy of antibiotics for endoscopic response in CD patients colonized with AIEC.</p><p><strong>Design: </strong>Patients with endoscopically active, ileal CD, colonized with AIEC, were randomized to receive oral ciprofloxacin and rifaximin or double placebo for 12 weeks. AIEC was detected in ileal biopsies, by phenotypic analysis. The primary endpoint was endoscopic overall response, as defined by a CD endoscopic index of severity adapted to patients with ileal CD. Central readers blinded to the treatment scored video recordings of colonoscopies at preinclusion and week 12. We expected a strong signal of efficacy for antibiotics in this subgroup of patients.</p><p><strong>Results: </strong>Between May 2016 and June 2021, 155 patients were screened, and 24 patients were randomized, 12 in each arm. All patients' AIEC were sensitive to ciprofloxacin and rifaximin in vitro. There was no statistical difference between the 2 arms for endoscopic overall response (50% in the Cipro-Rifa group vs 33% in the placebo group, estimated difference 17%; 95% CI, -23% to 51%). Within the antibiotics arm, 7/10 patients became AIEC- and 3/10 patients remained AIEC+ (and acquired resistance to ciprofloxacin), as compared to 7/12 AIEC- and 5/12 AIEC+ in the placebo arm, respectively. There was no association between AIEC clearance and endoscopic endpoints.</p><p><strong>Conclusions: </strong>A combination of ciprofloxacin and rifaximin was not superior to placebo to achieve endoscopic endpoints in patients with ileal CD colonized with AIEC.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144289779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Susceptibility to inflammatory bowel diseases promotes invasive carcinomas in a murine model of ATF6-driven colon cancer.","authors":"Janine Kövilein, Adam Sorbie, Sevana Khaloian, Vanessa Küntzel, Miriam von Stern, Mohamed Ahmed, Sebastian Jarosch, Marianne Remke, Amira Metwaly, Elena M Reuss, Dirk H Busch, Matthieu Allez, Katja Steiger, Barbara Schraml, Olivia I Coleman, Dirk Haller","doi":"10.1093/ecco-jcc/jjaf102","DOIUrl":"10.1093/ecco-jcc/jjaf102","url":null,"abstract":"<p><strong>Background and aims: </strong>Chronic inflammation in inflammatory bowel disease (IBD) patients represents a risk factor for developing colitis-associated cancer (CAC). We previously linked the endoplasmic reticulum unfolded protein response (UPRER) signal transducer activating transcription factor 6 (ATF6) with spontaneous microbiota-dependent colonic adenoma development in mice expressing epithelial-specific activated ATF6 (nATF6IEC).</p><p><strong>Methods: </strong>To investigate IBD-related risk factors in ATF6-mediated tumorigenesis, we crossed tumor-free monoallelic (tg/wt) nATF6IEC mice with interleukin-10 deficient mice (Il10-/-). We characterized our newly generated murine model under germ-free (GF) and specific pathogen-free (SPF) conditions, including tumor phenotype and immune cell characterizations, as well as complex human stool and minimal consortium colonizations.</p><p><strong>Results: </strong>IL-10 deficiency initiated tumor susceptibility, with 77% of 12-week tg/wt;Il10-/- mice developing colonic adenomas and invasive carcinomas in this novel CAC mouse model. Tumor formation correlated with mucosal immune cell infiltration, characterized by CD11b+ granulocytes and monocytes, and mucosa-associated dysbiosis. Colonization of germ-free nATF6IEC;Il10-/- mice with minimal biosynthetic consortia and IBD stool re-established CAC, confirming microbiota-dependent ATF6-driven tumorigenesis. Increased ATF6 expression in IBD patients during active disease highlights human relevance.</p><p><strong>Conclusion: </strong>Our findings show that IBD susceptibility heightens the risk for ATF6-driven tumorigenesis.</p>","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":"19 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12260500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy of JAK inhibitors in ulcerative colitis: tipping toward safe success.","authors":"Virginia Solitano, Laurent Peyrin-Biroulet, Silvio Danese","doi":"10.1093/ecco-jcc/jjaf114","DOIUrl":"https://doi.org/10.1093/ecco-jcc/jjaf114","url":null,"abstract":"","PeriodicalId":94074,"journal":{"name":"Journal of Crohn's & colitis","volume":"19 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}